Fundraising Fox
/Companies
Sign in

Aravax

Melbourne, AU · 20 employees on LinkedIn · 4 known investors

Find your way into Aravax

Sign up to see every warm intro you have to Aravax

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Aravax team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies. Founded on technology from Alfred Health and Monash University, it operates internationally with offices in Melbourne, Australia and Oxford, UK.

BiotechHealthtechMedical Devices

Founders & leadership

SPSara Prickett
Sara PrickettCo-founderSara Prickett is Chief Scientific Officer and Co-founder of Aravax, a clinical-stage biotechnology company developing immunotherapies for food allergies. She has held prior roles as Chief Operating Officer at Aravax and Senior Medical Research Scientist specializing in immunology, with research focused on understanding immune responses and translating findings into disease management approaches.

Investors · 4

Novartis Venture Fund✓ confirmed by AravaxBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · the company's own site · funding news · press coverage · Not right? Tell us

Tenmile✓ confirmed by Aravax

How we know: Tenmile's portfolio page · the company's own site · funding news · aravax.com.au · Not right? Tell us

UniSeed Pty Ltd.listed by UniSeed Pty Ltd.Brisbane · $165K – $330K

How we know: UniSeed Pty Ltd.'s portfolio page · the VCSheet dataset · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Aravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut Allergy - BioSpacebiospace.com · Aug 2026Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapyaravax.com.au · Jan 2024Aravax commences Phase 2 in peanut allergy with $20m Series B from Brandon Capital and Tenmilearavax.com.au · Dec 2022

Frequently asked questions

What does Aravax do?
Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies. Founded on technology from Alfred Health and Monash University, it operates internationally with offices in Melbourne, Australia and Oxford, UK.
Who founded Aravax?
Aravax was founded by Sara Prickett.
Who are Aravax's investors?
Aravax's investors include Breakthrough Victoria, Novartis Venture Fund, Tenmile, UniSeed Pty Ltd..
Where is Aravax headquartered?
Aravax is headquartered in Melbourne, AU.